Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of JS006 plus toripalimab with or without chemotherapy in advanced solid tumors
CTR20233490Phase 2Terminated
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of JS006 in Nonhematologic neoplasms and non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Shanghai Junshi Biosciences Co., Ltd. Primary endpoints: Safety and tolerability in Cohort 1, Recommended phase II dose (RP2D) in Cohort 1 and 1 more. Started Nov 2023; status: terminated.
02
Drugs
JS006
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20233490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233490.